Navigation Links
Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Date:9/30/2008

CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) will discuss the fourth quarter and year end financial results for the fiscal year ended June 30, 2008 and provide an update on corporate developments during a conference call and webcast on September 30, 2008 at 11:15 a.m. ET.

Conference Call and Webcast Access Information

-- Q4-Fiscal Year 2008 Conference September 30, 2008 at

Call - Live 11:15 a.m. ET

Domestic Dial-In Number 1-888-263-2958

International Dial-In Number 1-913-312-6664

-- Q4-Fiscal Year 2008 Conference September 30 - October 7, 2008

Call - Replay

Domestic Dial-In Number 1-888-203-1112

International Dial-In Number 1-719-457-0820

Replay Passcode: 6671824

-- Webcast Live and Replay Access http://www.palatin.com

The webcast and replay can be accessed by logging on to the "Investor Center-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
3. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
4. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
5. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
6. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
7. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
8. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
9. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
10. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017  On January 10 at the Medtech ... Morgan Healthcare Conference in San Francisco ... , spoke to pharmaceutical leaders and public and private ... break down and destroy biofilms.  Biofilms ... antibiotics and the body,s immune system from eradicating chronic ...
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. ... Tracey, MD , president and CEO of The ... completed an analysis of how the nervous system regulates ... and develop bioelectronic medicine devices to treat ... Nature Neuroscience . The paper examines ...
(Date:1/16/2017)...  Eurofins Genomics today announced the expansion of its ... receive their primers in a shorter turnaround time, without ... with other providers. Express oligos are available for anyone ... no additional fee. Researchers use the oligos ... sequencing, genotyping, site-directed mutagenesis, and cloning. Often, they are ...
(Date:1/14/2017)... , Jan. 13, 2017  The Alliance for Safe ... response to FDA final guidance on biologic ... continued leadership in emphasizing the importance of distinct naming ... aware of the benefits biosimilars will bring to patients, ... Yet the portion of the Guidance dealing with ...
Breaking Biology Technology:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
Breaking Biology News(10 mins):